NIP
ORIC icon

Nicholas Investment Partners’s Oric Pharmaceuticals ORIC Stock Holding History

Nicholas Investment Partners’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-220,735
Closed -$2.65M – 238
2025
Q3 		$2.65M Buy
220,735
+146,493
+197% +$1.54M 0.2% 153
2025
Q2 		$754K Sell
74,242
-80,137
-52% -$538K 0.07% 195
2025
Q1 		$861K Buy
+154,379
New +$1.35M 0.09% 163
2024
Q2 		– Sell
-183,494
Closed -$2.52M – 229
2024
Q1 		$2.52M Buy
+183,494
New +$2.18M 0.26% 136

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nicholas Investment Partners's ORIC Position: Q4 2025 in Review

Nicholas Investment Partners sold out of Oric Pharmaceuticals (ORIC) in Q4 2025, closing a stake of 220,735 shares — an estimated $2.65M sold.

Nicholas Investment Partners first reported a position in ORIC in Q1 2024 and held it in 4 quarters. The position peaked at $2.65M in Q3 2025. 164 funds tracked by Wall St. Rank hold ORIC as of Q4 2025.

  • Nicholas Investment Partners reported no remaining Oric Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Nicholas Investment Partners sold 220,735 Oric Pharmaceuticals shares in Q4 2025, an estimated $2.65M.
  • Nicholas Investment Partners first reported a position in Oric Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Nicholas Investment Partners's Oric Pharmaceuticals position peaked at $2.65M in Q3 2025.
  • 164 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q4 2025.

Based on Nicholas Investment Partners's 13F filing for Q4 2025, filed 13 Feb 2026.